Chen B, Wu JX, Cheng SH, et al. - Findings demonstrate effectiveness, good tolerability as well as promising role of adjuvant radiotherapy as an adjuvant regimen in patients with HCC who have undergone narrow-margin hepatectomy.

• This single-arm, prospective phase 2 trial involved 76 eligible patients receiving intensity-modulated radiotherapy (IMRT) for HCC after narrow-margin hepatectomy.

• Patients underwent IMRT within 4-6 weeks post-surgical resection.

• The 3-year overall survival (OS) and disease-free survival (DFS) rates were noted to be 88.2% and 68.1%, respectively; and the 5-year OS and DFS rates were estimated to be 72.2% and 51.6%, respectively.

• No marginal recurrence occurred, and at the first relapse, there were intrahepatic, extrahepatic, and combined recurrences in 33, 5, and 1 patient, respectively.

• Leukopenia (7.9%), elevated alanine aminotransferase (3.9%) and aspartate aminotransferase (2.6%) levels, and thrombocytopenia (1.3%) occurred as the most common radiation-related grade-3 toxicities.

• Classical or nonclassical radiation-induced liver disease was not reported.